MarkL.SundermeyerMD
Oncology • Saint Louis, MOBreast Cancer, Gastrointestinal Cancer, Genitourinary Oncology
Associate Professor
Dr. Sundermeyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 800-647-2098Fax+1 314-362-3192
Summary
- Mark Sundermeyer, MD, is an oncologist based in Saint Louis, MO, with subspecialties in breast cancer, gastrointestinal cancer, and genitourinary oncology. He completed his internal medicine residency and hematology/medical oncology fellowship at Temple University Hospital and Fox Chase Cancer Center. Dr. Sundermeyer has held positions as Associate Professor at Washington University, Medical Director at CMH-OHSU Knight Cancer Collaborative, and Deputy Chief at Asplundh Cancer Pavilion. He has expertise in hematology, medical oncology, and thoracic oncology. His research has been published in several prestigious journals and cited extensively. His honors include being named a Top Doctor by Philadelphia Magazine.
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006- Temple University HospitalResidency, Internal Medicine, 2000 - 2003
University of Missouri-Columbia School of MedicineClass of 2000
Certifications & Licensure
IL State Medical License 2024 - 2026
MO State Medical License 2023 - 2026
OR State Medical License 2020 - 2025
WA State Medical License 2021 - 2024
PA State Medical License 2001 - 2021
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Philadelphia Magazine Top Doctor Philadelphia Magazine, 2018-2020
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Publications & Presentations
PubMed
- 23 citationsChemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data BaseAlina M. Mateo, Todd A. Pezzi, Mark L. Sundermeyer, Cynthia A. Kelley, V. Suzanne Klimberg
Annals of Surgical Oncology. 2017-04-01 - 9 citationsAtypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3,976 cases from the National Cancer Data...Alina M. Mateo, Todd A. Pezzi, Mark L. Sundermeyer, Cynthia A. Kelley, Vicki Klimberg
Journal of Surgical Oncology. 2016-10-01 - 8 citationsAnalysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.Naveed Ali, Faizan Malik, Syed Imran Mustafa Jafri, Mary Naglak, Mark L. Sundermeyer
Clinical Lymphoma, Myeloma & Leukemia. 2016-09-01
Press Mentions
Scarpaci Joins Abington Cancer Care SpecialistsJanuary 13th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
